RxDoctor Payments DataLook up a doctor →

Julie Peterson, APRN

Psychiatric/Mental Health · Lakeland, FLNPI 1801357066

Payments from drug & device makers

$13,432in general payments, 2019–2025

Across 629 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$943
  • Lilly USA, LLC$906
  • Amgen$828
  • Otsuka America Pharmaceutical, Inc.$611
  • plus $7K from 38 others

What the payments were for

  • Food & beverage$13,412100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,432 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$20,090
Medicare patients
101
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$23,598
MounjaroTirzepatide14$21,057
VraylarCariprazine Hcl13$19,594
EliquisApixaban18$10,103
Mirtazapine25$645
Duloxetine Hcl11$329
Trazodone Hcl28$320
Omeprazole18$281
Fluticasone Propionate14$281
Buspirone Hcl22$280
Hydroxyzine Hcl21$270
Atorvastatin Calcium22$251
Escitalopram Oxalate23$223
Quetiapine Fumarate21$207
Pantoprazole Sodium13$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,582$23,59818 claims
Lilly USA, LLCMounjaro$906$21,05714 claims
AbbVieVraylar$1,106$19,59413 claims
PfizerEliquis$548$10,10318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →